HtrA serine proteases as potential therapeutic targets in cancer.
HtrA serine proteases as potential therapeutic targets in cancer.
复制标题
HTRA丝氨酸蛋白酶作为癌症的潜在治疗靶标。
DOI：
10.2174/156800909788486704
复制
发表时间：
2009-06
影响因子：
3
通讯作者：
Baldi A
中科院分区：
文献类型：
--
作者：
Chien J;Campioni M;Shridhar V;Baldi A
丝氨酸蛋白酶的人类HtrA家族由四个成员组成：HtrA1、HtrA2、HtrA3和HtrA4。虽然原核HtrA蛋白的特征在于其作为分子伴侣和降解周质中错误折叠蛋白的蛋白酶的双重作用，但哺乳动物HtrA蛋白的一些成员被描述为程序性细胞死亡和化疗诱导的细胞毒性的潜在调节剂。这篇综述文章的目的是描述与这些HtrA丝氨酸蛋白酶相关的分子改变，以及这些改变如何与肿瘤行为和对化疗的反应相关。我们还将讨论化疗药物调节HtrA丝氨酸蛋白酶的表达和激活，这些蛋白酶有助于程序性细胞死亡的证据。最后，我们将讨论表观遗传疗法在靶向HtrA丝氨酸蛋白酶的表达和激活中的潜在作用，以及这些蛋白酶增强常规化疗的细胞毒性作用的机制。
The human HtrA family of serine proteases consists of four members: HtrA1, HtrA2, HtrA3 and HtrA4. Although prokaryotic HtrA proteins are well characterized in their dual roles as chaperones and proteases that degrade misfolded proteins in the periplasm, some members of mammalian HtrA proteins are described as potential modulators of programmed cell death and chemotherapy-induced cytotoxicity. Goal of this review article is to describe the molecular alterations associated with these HtrA serine proteases and how these alterations may be associated with tumor behavior and response to chemotherapy. We will also discuss evidence that chemotherapeutic drugs regulate the expression and activation of HtrA serine proteases and that these proteases contributes to programmed cell death. Finally, we will discuss the potential role of epigenetic therapy in targeting the expression and activation of HtrA serine proteases and the mechanisms by which these proteases enhance cytotoxic effect of conventional chemotherapy.
登录
查看更多内容
影响因子：
11.5
作者：
Cutcliffe, C;Kersey, D;Perlman, EJ
通讯作者：
Perlman, EJ
影响因子：
16
作者：
Bartke, T;Pohl, C;Jentsch, S
通讯作者：
Jentsch, S
DOI：
10.1152/ajprenal.00154.2004
发表时间：
2005-02-01
影响因子：
4.2
作者：
Cilenti, L;Kyriazis, GA;Zervos, AS
通讯作者：
Zervos, AS
影响因子：
11.4
作者：
Andersson, A.;Ritz, C.;Fioretos, T.
通讯作者：
Fioretos, T.
影响因子：
50.3
作者：
Chin, Koei;DeVries, Sandy;Gray, Joe W.
通讯作者：
Gray, Joe W.